Literature DB >> 10172359

The reimbursement of the expenses for medical treatment received by 'transnational' patients in EU-countries.

K Kesteloot1, S Pocceschi, E van der Schueren.   

Abstract

The number of 'transnational' EU-patients, i.e. EU-citizens receiving medical treatment in another country than their working state--where they contribute for social security--is growing steadily. This article describes the EU and member states' rules governing the reimbursement of the expenses for medical treatment received abroad, for the case where patients travel abroad with the sole purpose of medical care in the framework of the national health insurance (treatment authorised by E112-form). It is illustrated that some countries' national rules comply with the EU-rules, a number of countries apply stricter rules, while other EU-members have established legislation that is more favourable for their citizens, than the EU-rules. Furthermore, the financial burden of treatment abroad also differs widely, since some countries reimburse travel and living expenses for the patient, and sometimes also for an accompanying person, while other countries do not provide such reimbursements. The article concludes with some policy implications.

Entities:  

Mesh:

Year:  1995        PMID: 10172359     DOI: 10.1016/0168-8510(94)00681-4

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  1 in total

Review 1.  Outstanding regulatory aspects in the European pharmaceutical market.

Authors:  P Kanavos; E Mossialos
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.